Compare Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Sht-Term Inflation-Protected Sec Idx ETF vs Zoetis Inc — how do they compare? Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.69, while Zoetis Inc trades at $72.48 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VTIP | ZTS | |
|---|---|---|
52-Week High | $50.75 | $156.76 |
52-Week Low | $49.39 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTIP trades at $49.705, up 0.05% on the day, with a neutral technical signal overall. The ETF focuses on short-term inflation-protected securities, designed to hedge against rising costs. Recent news highlights institutional buying interest, with 55 North Private Wealth increasing its stake by 12.2% as of August 2026 (SEC filing).
The outlook for VTIP is supported by persistent inflation above the Fed's target, offering a potential hedge. Risks include interest rate uncertainty and competition from other bond ETFs. Analyst sentiment is cautiously positive, emphasizing its role in inflation-sensitive portfolios amid current economic conditions.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
